Browse the evidence

Time since Type 2 Diabetes diagnosis is a significant moderator of absolute peak oxygen uptake, with longer duration associated with greater reductions in fitness.

The longer you have Type 2 Diabetes, the more your maximum oxygen uptake tends to drop. However, this decline is gradual. Prioritize exercise early in your diagnosis to preserve fitness, as the most significant drops may occur within the first 5 years.

Alternative forms of creatine (e.g., creatine HCl, creatine ethyl ester, creatine malate) are not superior to creatine monohydrate (CM) in increasing muscle creatine content or improving exercise performance, despite marketing claims suggesting otherwise.

If you are buying creatine, stick to creatine monohydrate (CM). Alternative forms like creatine HCl, ethyl ester, or malate are marketed as superior, but scientific evidence shows they are not better at increasing muscle creatine or improving performance than standard CM. You are likely paying significantly more (up to 116% higher per gram) for no additional benefit.

Adherence to a Mediterranean diet (MedDiet) mitigates the increased risk of type 2 diabetes and metabolic dysfunction associated with the TCF7L2 rs7903146 T-allele, effectively neutralizing the genetic predisposition when adherence is high.

If you carry the TCF7L2 rs7903146 T-allele (a common genetic variant linked to higher diabetes risk), strict adherence to a Mediterranean-style diet is your most powerful tool. It doesn't just help; it specifically neutralizes the genetic disadvantage, keeping your weight, waist circumference, and diabetes risk in check. Focus on high adherence to this pattern rather than just isolated nutrients.

GLP-1 RA treatment is associated with significant lean tissue (muscle) loss, with studies showing 14-40% of total weight loss being lean mass, necessitating interventions to preserve muscle.

While GLP-1 RAs are effective for weight loss, they also cause muscle loss (14-40% of total weight loss). To protect your strength and metabolism, it is crucial to consume adequate protein and engage in resistance exercise during treatment. This is especially important for older adults or those already at risk of muscle loss.

Reduced gut microbial diversity (alpha-diversity) and specific taxonomic shifts (e.g., depletion of Akkermansia muciniphila and Faecalibacterium prausnitzii) are consistently associated with obesity and metabolic syndrome, serving as a marker of a less resilient microbiome.

Focus on dietary patterns that support microbial diversity (e.g., fiber-rich diets) rather than seeking simple diagnostic ratios. A diverse diet supports a resilient microbiome, which is associated with better metabolic health.

Continuous Positive Airway Pressure (CPAP) therapy effectively improves daytime sleepiness and quality of life in Obstructive Sleep Apnoea (OSA) patients, but its impact on cardiometabolic outcomes is uncertain and secondary prevention trials have failed to demonstrate significant modification of cardiovascular events.

CPAP is the most effective treatment for stopping snoring and fixing daytime sleepiness in OSA patients. However, do not expect it to automatically fix your heart health or blood sugar levels, as evidence for those benefits is weak. If you struggle with the mask, talk to your doctor about alternatives like oral appliances or nerve stimulation, as adherence is a major hurdle.

Physical activity and exercise provide significant health benefits for adults with overweight or obesity independent of weight loss, including improvements in body composition quality, cardiorespiratory fitness, and metabolic health.

Prioritize regular physical activity regardless of your current weight. Focus on building cardiorespiratory fitness and muscle strength, as these provide health benefits even if you do not lose weight. Do not let the absence of scale movement discourage you from exercising.

GLP-1 receptor agonists and incretin co-agonists reduce total body weight primarily through adipose tissue loss, but this process involves an absolute reduction in lean mass (skeletal muscle) that typically accounts for 20–30% of the total weight lost.

If you are taking GLP-1 medications, expect to lose some muscle along with fat. To minimize this, prioritize resistance training and adequate protein intake. This helps preserve strength and metabolic health despite the inevitable lean mass reduction.

Tirzepatide significantly reduces the apnea-hypopnea index (AHI) and body weight in patients with moderate to severe obstructive sleep apnea (OSA) and obesity, regardless of whether they are using positive airway pressure (PAP) therapy.

If you have moderate to severe sleep apnea and obesity, Tirzepatide is a newly FDA-approved treatment that significantly reduces breathing interruptions during sleep and leads to substantial weight loss (18-20%). It works not just by shrinking fat around the airway, but also by reducing inflammation and affecting brain signals related to sleep. You can use it alone or alongside your CPAP machine. Because rapid weight loss can affect muscle, you should combine this medication with strength training and nutritional counseling.

GLP-1 receptor agonists (specifically Liraglutide) improve OSA outcomes when used in combination with CPAP, but CPAP alone is superior to Liraglutide monotherapy for reducing cardiovascular inflammation and plaque volume.

If you have severe sleep apnea and diabetes, adding Liraglutide to your CPAP therapy can further reduce breathing interruptions compared to using Liraglutide alone. However, CPAP is still necessary for protecting your heart and reducing arterial plaque, as Liraglutide alone does not provide this specific cardiovascular benefit. If you struggle with CPAP, discuss combination strategies with your doctor.

Long-term maintenance of cardiorespiratory fitness (CRF) improves insulin sensitivity in men with visceral obesity, even when visceral adipose tissue (VAT) rebounds.

Focus on maintaining your aerobic fitness (cardiorespiratory fitness) rather than obsessing over small fluctuations in body fat. If you maintain your fitness level, your body's ability to handle insulin remains high, even if you regain some visceral fat. Prioritize consistent physical activity over strict weight maintenance.

Reductions in intramuscular fat (specifically core and psoas low-attenuation muscle area) are associated with improved insulin resistance, independent of visceral fat changes.

Exercise helps reduce fat stored within muscles (intramuscular fat), which directly improves how your body uses insulin. This benefit occurs even if you don't lose all your belly fat.

Noninvasive tests (FIB-4, ELF, MRE) are recommended for screening and risk stratification of MASLD, with FIB-4 as the first-line assessment due to its simplicity and cost-effectiveness.

If you have metabolic risk factors like obesity or type 2 diabetes, ask your doctor for a FIB-4 score. It is a simple, low-cost calculation using age, AST, ALT, and platelet count that helps identify liver fibrosis risk early.

Endoscopic bariatric therapies (EBMTs), including intragastric balloons and endoscopic sleeve gastroplasty, provide significant weight loss and metabolic improvements as minimally invasive alternatives to surgery, though they are associated with specific adverse events and potential weight regain.

Endoscopic bariatric therapies are a viable, minimally invasive option for weight loss, particularly for those who cannot or will not undergo surgery. Procedures like intragastric balloons and endoscopic sleeve gastroplasty can achieve significant weight loss (25-60% excess weight loss) when combined with lifestyle changes. However, they are not risk-free, with potential side effects ranging from nausea to rare serious complications. Patients should discuss their BMI, health status, and preference for invasiveness with a specialist to determine if an EBMT is appropriate, keeping in mind that some devices are temporary and may require combination with medication or surgery for long-term success.

GLP-1 receptor agonist therapy induces lean mass loss proportional to fat loss (approx. 25% of total weight loss), which is a physiological response to caloric restriction rather than a unique pathological catabolic effect of the drug.

If you are taking a GLP-1 drug like Semaglutide, expect to lose about 25% of your total weight as muscle. This is normal and similar to losing weight through diet alone. To protect your muscle, prioritize resistance training and eat 1.2-1.6g of protein per kg of body weight daily.

Preservation of skeletal muscle mass is a critical consideration in obesity treatment with second-generation medications, and new drugs (e.g., bimagrumab) are being developed to block muscle loss.

When you lose weight, you might lose some muscle. This is a concern, especially for older adults. New treatments are being developed to help preserve muscle mass while you lose fat. Talk to your doctor about strategies to maintain muscle strength during weight loss.

The most commonly consumed dietary supplements among bodybuilders are Vitamin C, Vitamin D, and Whey Protein.

If you are a bodybuilder, you are likely taking Vitamin C, Vitamin D, and Whey Protein. Ensure your dosage of these is appropriate for your body weight and health status, and do not exceed recommended daily allowances without medical supervision.

Higher intake of red or processed meat is associated with increased all-cause, cardiovascular, and cancer-related mortality, but this association is largely explained by confounding factors such as smoking, obesity, and alcohol consumption rather than the protein itself.

While high intake of red and processed meats is linked to higher mortality, this risk appears to be driven largely by associated lifestyle factors like smoking, obesity, and alcohol use rather than the protein itself. Focus on maintaining a healthy weight, avoiding smoking, and limiting alcohol, as these factors likely explain the observed risks more than the meat consumption alone.

Higher intake of poultry, milk, and cheese is associated with reduced mortality risk in unadjusted models, but this protective effect is also substantially attenuated after adjusting for lifestyle confounders.

While high intake of poultry, milk, and cheese is linked to lower mortality in initial analyses, this benefit appears to be driven largely by associated lifestyle factors like not smoking, healthy weight, and moderate alcohol use rather than the food itself. Focus on maintaining a healthy lifestyle, as these factors likely explain the observed benefits more than the specific foods alone.

Semaglutide induces body weight loss and metabolic remodeling beyond caloric restriction alone, driven by intake-independent mechanisms including adipose tissue browning, increased sympathetic innervation, and sustained locomotor activity.

Semaglutide provides metabolic benefits that go beyond simply eating less. It promotes fat loss through biological changes like increasing brown fat activity and reducing fat cell size, independent of how much you eat. This suggests that patients may achieve better results with semaglutide than with dieting alone, even if their food intake is similar.

Shifting the Australian population's BMI to an optimal level of ≤25 kg/m² yields substantial health gains, specifically 2.00 million undiscounted Health Adjusted Life Years (HALYs) over 20 years and 20.4 million over the remaining lifetime.

For public health policy, this simulation confirms that population-wide strategies to maintain a BMI under 25 kg/m² are among the most effective interventions for extending healthy life. The benefits are not just individual but systemic, significantly reducing the burden of chronic diseases like heart disease, diabetes, and osteoarthritis, with the greatest relative health improvements occurring in socioeconomically disadvantaged communities.

In oncology patients, muscle-specific strength (MSS) estimated via anthropometry (body weight or calf circumference) or bioimpedance (BIA) provides a reliable alternative to DXA-derived MSS, enabling functional assessment in resource-limited settings.

For cancer patients or clinicians without access to DXA scanners, you can accurately estimate muscle quality by dividing handgrip strength by body weight or calf circumference. This method correlates very strongly with the gold standard DXA test, allowing for effective monitoring of sarcopenia and treatment response in routine clinical settings.

Lean MASLD (normal BMI but with metabolic dysfunction) is a distinct phenotype driven by sarcopenia, adverse fat distribution, and genetic susceptibility, requiring different treatment strategies than obesity-driven MASLD.

If you have a normal BMI but metabolic issues (like high blood sugar or blood pressure), you can still develop fatty liver disease. This 'lean MASLD' is often linked to low muscle mass and genetics. Focus on building muscle and managing metabolic health rather than just losing weight.

Dietary weight loss stabilizes the proportion of lean mass lost (%LML) at approximately 25-33% once total weight loss exceeds 5%, contradicting the hypothesis that lean loss increases proportionally with greater weight loss.

When you lose weight through diet, you will lose some muscle along with fat. This is normal and accounts for about 25-33% of the total weight lost, regardless of how much weight you lose. Men tend to lose a slightly higher percentage of lean mass than women. To minimize this, combine your diet with resistance training and adequate protein intake, but do not fear that larger weight loss equals disproportionately larger muscle loss.